UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark one) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from: to Commission File Number: 001-06064 ALEXANDERS INC (Exact name of registrant as specified in its charter) Delaware 51-0100517 | --- | --- | --- | |--------- ...

Evorpacept is the first CD47 blocker to show durable clinical benefit and a well-tolerated safety profile in a prospective randomized trial Evorpacept combination achieved a confirmed overall response rate (ORR) of 40.3% compared to 26.6% for the control arm and demonstrated a median duration of response of 15.7 months compared to 7.6 months in the full trial populationIn the pre-specified population of patients with fresh HER2-positive biopsies, evorpacept combination showed the greatest benefit with ORR o ...

PARAMUS, N.J., July 31, 2024 (GLOBE NEWSWIRE) -- Alexander’s, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on August 30, 2024 to stockholders of record on August 12, 2024. Alexander’s, Inc. is a real estate investment trust that has five properties in the New York City metropolitan area. CONTACT:GARY HANSEN(201) 587-8541 Certain statements contained herein constitute forward-looking statements as such term is defined in Sec ...

Conference Call and Webcast Today at 4:30 PM EDT SOUTH SAN FRANCISCO, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, announced that the Company will host an investor conference call and webcast today at 4:30 PM EDT to share topline data results from the Phase 2 ASPEN-06 clinical trial evaluating evorpacept for the treatment of advanced HER2- ...

PARAMUS, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE:ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended June 30, 2024 with the U.S. Securities and Exchange Commission and issue its second quarter earnings release on Monday, August 5, 2024, before the New York Stock Exchange opens. Vornado Realty Trust (NYSE:VNO), the manager which conducts Alexander's operations, announced it will host its quarterly earnings conference call and an audio webcast ...

SHansche Thus far this year, Office REITs have gained modestly, returning an average of 5.23% (most of that coming last week), compared to the REIT average of 1.07%. This stands in sharp contrast to the +18.55% return posted by the S&P 500, and even sharper contrast to the +21.20% earned by the Nasdaq 100. Hoya Capital Income BuilderThe WFH (work from home) trend kickstarted by the pandemic has had, and will continue to have, lasting effects on commercial office owners, as demand has slackened, more or l ...

holicow/E+ via Getty Images If you have read my recent articles, you know that I am expecting a major sell-off in REITs over the next 2 - 5 years. As the graph below shows, the REIT rally that began in October, fueled by expectations of multiple rate cuts by the Fed, is showing signs of fizzling out. VNQ price chart (Seeking Alpha Premium) This is a 180-degree about-face from my outlook at the beginning of this year. I base this new expectation primarily on the technicals, but also on a looming crisi ...

DNY59 Topline Summary and Update ALX Oncology (NASDAQ:ALXO) is a cancer-focused biotech I've expressed deep skepticism in over the course of various articles, stating unequivocally that I did not feel that the risk to reward ratio was appropriate at the billion-plus market cap that the company was commanding as a phase 2 entity. They had generated compelling findings in their early trial readouts, but the CD47-based approach carries too much baggage for me to get too excited. Since then, the company's va ...

ALX Resources Corp. Receives Analytical Results from the Gibbons Creek Uranium Project, Athabasca Basin, SaskatchewanJune 13, 2024 7:30 AM EDT | Source: ALX Resources Corp.Vancouver, British Columbia--(Newsfile Corp. - June 13, 2024) - ALX Resources Corp. (TSXV: AL) (FSE: 6LLN) (OTC: ALXEF) ("ALX" or the "Company") is pleased to announce the results of the 2024 winter drilling program and upcoming summer 2024 exploration plans at its Gibbons Creek Uranium Project ("Gibbons Creek", or the "Proj ...

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that management will participate in the Jefferies Global Healthcare Conference. Details are as follows: Format: Fireside chat with analyst, Michael Yee and 1x1 Investor MeetingsDate: Wednesday, June 5, 2024 Time: 1:00 PM ET Location: New York, NY Webcast link: ...